• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Steroid-induced myopathy in left-sided ulcerative colitis. Successful treatment and continued therapy with the topical steroid budesonide].

作者信息

Caesar I, Gross V, Roth M, Andus T, Hohenberger W, Schölmerich J

机构信息

Klinik und Poliklinik für Innere Medizin I, Universität Regensburg.

出版信息

Med Klin (Munich). 1997 Jun 15;92(6):358-62. doi: 10.1007/BF03044778.

DOI:10.1007/BF03044778
PMID:9297069
Abstract

BACKGROUND

Glucocorticoids are an effective treatment of ulcerative colitis. The occurrence of steroid side effects depends on dosage and duration of steroid treatment. It may be a high as 80%. A rare side effect of glucocorticoid therapy is steroid induced myopathia. There exists an acute and a chronic form of steroid induced myopathia. Chronic steroid myopathia affects mainly the proximal musculature of the lower and upper extremities and leads to proximal muscle weakness. Histologically, an atrophy of type IIb-muscle fibers can be found. Chronic steroid myopathia occurs after prolonged treatment with higher doses of glucocorticoids.

CASE REPORT

The case report describes a 25 year old male patient with left-sided ulcerative colitis who developed chronic steroid myopathia after several months of glucocorticoid treatment. After switching from systemic steroids to budesonide the symptoms of myopathia disappeared. Left-sided ulcerative colitis remained in remission.

CONCLUSION

The case documents the disappearance of a severe steroid side effect after switching from a systemic steroid to budesonide.

摘要

相似文献

1
[Steroid-induced myopathy in left-sided ulcerative colitis. Successful treatment and continued therapy with the topical steroid budesonide].
Med Klin (Munich). 1997 Jun 15;92(6):358-62. doi: 10.1007/BF03044778.
2
Budesonide enema in distal ulcerative colitis. A randomized dose-response trial with prednisolone enema as positive control. The Danish Budesonide Study Group.布地奈德灌肠剂治疗远端溃疡性结肠炎。以泼尼松龙灌肠剂作为阳性对照的随机剂量反应试验。丹麦布地奈德研究组。
Scand J Gastroenterol. 1991 Dec;26(12):1225-30. doi: 10.3109/00365529108998618.
3
Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis.
Gastroenterology. 1996 Jun;110(6):1713-8. doi: 10.1053/gast.1996.v110.pm8964395.
4
[Locally acting glucocorticoids in chronic intestinal inflammation].[局部作用的糖皮质激素在慢性肠道炎症中的应用]
Ned Tijdschr Geneeskd. 1994 Dec 17;138(51):2533-5.
5
Oral budesonide therapy for ulcerative colitis: a topical tale.溃疡性结肠炎的口服布地奈德治疗:一个局部用药的故事。
Gastroenterology. 1996 Jun;110(6):2000-2. doi: 10.1053/gast.1996.v110.agast962000.
6
Complete mucosal healing of distal lesions induced by twice-daily budesonide 2-mg foam promoted clinical remission of mild-to-moderate ulcerative colitis with distal active inflammation: double-blind, randomized study.每日两次布地奈德 2 毫克泡沫剂诱导的远端病变完全黏膜愈合促进伴有远端活动性炎症的轻中度溃疡性结肠炎的临床缓解:双盲、随机研究。
J Gastroenterol. 2018 Apr;53(4):494-506. doi: 10.1007/s00535-017-1376-4. Epub 2017 Aug 4.
7
Oral budesonide for induction of remission in ulcerative colitis.口服布地奈德诱导溃疡性结肠炎缓解
Cochrane Database Syst Rev. 2010 Oct 6(10):CD007698. doi: 10.1002/14651858.CD007698.pub2.
8
Oral budesonide therapy for steroid-dependent ulcerative colitis: a pilot trial.口服布地奈德治疗激素依赖型溃疡性结肠炎:一项试点试验。
Aliment Pharmacol Ther. 1997 Dec;11(6):1047-52. doi: 10.1046/j.1365-2036.1997.00263.x.
9
Topical anticolitic efficacy and selectivity of the glucocorticoid budesonide in a new model of acetic acid-induced acute colitis in the rat.
Aliment Pharmacol Ther. 1994 Aug;8(4):433-41. doi: 10.1111/j.1365-2036.1994.tb00311.x.
10
Budesonide versus prednisolone retention enemas in active distal ulcerative colitis.
Aliment Pharmacol Ther. 1994 Dec;8(6):623-9. doi: 10.1111/j.1365-2036.1994.tb00340.x.

引用本文的文献

1
Replacement of conventional glucocorticoids by oral pH-modified release budesonide in active and inactive Crohn's disease: results of an open, prospective, multicenter trial.
Dig Dis Sci. 2003 Feb;48(2):373-8. doi: 10.1023/a:1021900115403.

本文引用的文献

1
HISTOLOGICAL AND HISTOCHEMICAL CHANGES IN THE MUSCLES OF RABBITS GIVEN THE CORTICOSTEROID TRIAMCINOLONE.给予皮质类固醇曲安西龙的兔子肌肉的组织学和组织化学变化
Neurology. 1964 Sep;14:857-63. doi: 10.1212/wnl.14.9.857.
2
An assessment of prednisone, salazopyrin, and topical hydrocortisone hemisuccinate used as out-patient treatment for ulcerative colitis.对泼尼松、柳氮磺胺吡啶和局部用半琥珀酸氢化可的松作为溃疡性结肠炎门诊治疗药物的评估。
Gut. 1960 Sep;1(3):217-22. doi: 10.1136/gut.1.3.217.
3
Cortisone in ulcerative colitis; final report on a therapeutic trial.
可的松治疗溃疡性结肠炎;一项治疗试验的最终报告
Br Med J. 1955 Oct 29;2(4947):1041-8. doi: 10.1136/bmj.2.4947.1041.
4
Treatment of active Crohn's disease with an oral slow-release budesonide formulation.
Am J Gastroenterol. 1993 Jun;88(6):968-9.
5
Cyclosporine in severe ulcerative colitis refractory to steroid therapy.环孢素用于对类固醇治疗无效的重度溃疡性结肠炎。
N Engl J Med. 1994 Jun 30;330(26):1841-5. doi: 10.1056/NEJM199406303302601.
6
A comparison of budesonide with prednisolone for active Crohn's disease.布地奈德与泼尼松龙治疗活动期克罗恩病的比较。
N Engl J Med. 1994 Sep 29;331(13):842-5. doi: 10.1056/NEJM199409293311304.
7
Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group.口服布地奈德治疗活动性克罗恩病。加拿大炎症性肠病研究组。
N Engl J Med. 1994 Sep 29;331(13):836-41. doi: 10.1056/NEJM199409293311303.
8
Course of ulcerative colitis: analysis of changes in disease activity over years.溃疡性结肠炎的病程:多年来疾病活动度变化分析
Gastroenterology. 1994 Jul;107(1):3-11. doi: 10.1016/0016-5085(94)90054-x.
9
Disuse atrophy of skeletal muscle is associated with an increase in number of glucocorticoid receptors.
Endocrinology. 1980 Nov;107(5):1649-51. doi: 10.1210/endo-107-5-1649.
10
Acute hydrocortisone myopathy.急性氢化可的松肌病
Br Med J. 1980 Jul 26;281(6235):271-2. doi: 10.1136/bmj.281.6235.271-a.